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Mass spectrometry (MS)-based ubiquitinomics provides system-level understanding of
ubiquitin signaling. Here we present a scalable workflow for deep and precise in vivo ubi-
quitinome profiling, coupling an improved sample preparation protocol with data-
independent acquisition (DIA)-MS and neural network-based data processing specifically
optimized for ubiquitinomics. Compared to data-dependent acquisition (DDA), our method
more than triples identification numbers to 70,000 ubiquitinated peptides in single MS runs,
while significantly improving robustness and quantification precision. Upon inhibition of the
oncology target USP7, we simultaneously record ubiquitination and consequent changes in
abundance of more than 8,000 proteins at high temporal resolution. While ubiquitination of
hundreds of proteins increases within minutes of USP7 inhibition, we find that only a small
fraction of those are ever degraded, thereby dissecting the scope of USP7 action. Our method
enables rapid mode-of-action profiling of candidate drugs targeting DUBs or ubiquitin ligases
at high precision and throughput.
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The ubiquitin-proteasome system (UPS) consists ofnumerous proteins, including ubiquitin ligases, ubiquitinproteases (also termed deubiquitinases or DUBs) and the
proteasome. Approximately 750 enzymes mediate ubiquitin
attachment to and its cleavage from target proteins and regulate a
myriad of intracellular processes, such as cell cycle progression,
selective autophagy, or the response to growth factors1. Conse-
quently, dysregulation of the UPS can contribute to loss of cell
cycle control and ultimately to carcinogenesis2. On the other
hand, different components of the UPS are targets for anticancer
drugs. For example, many proteasome inhibitors and E3 ligase
modulators are clinically approved, the latter ones being of high
interest because they can be exploited for degrading proteins
otherwise considered undruggable3,4.
Ubiquitin is attached via its C-terminal carboxyl group to
lysine (K) side chains and protein N-termini to produce a
monoubiquitinated target protein. As each ubiquitin molecule
contains eight ubiquitin attachment sites (seven K residues within
and one at its amino terminus), consecutive linkage of additional
ubiquitin monomers leads to the formation of polymeric chains.
Polyubiquitin chains can form on each of these K residues and
encode for specific signals. For example, while K11- and K48-
linked chains can tag proteins for proteasomal degradation,
attachment of K63-linked ubiquitin conjugates to target proteins
tends to modulate protein-protein interactions5.
While early studies on ubiquitinated proteins were conducted
on a target-by-target basis, mass spectrometry (MS)-based pro-
teomics has facilitated global ubiquitin signaling profiling, such as
B-cell receptor signaling6,7. The primary method for ubiquiti-
nome analyses relies on immunoaffinity purification and MS-
based detection of diglycine-modified peptides (K-GG), generated
by tryptic digestion of ubiquitin-modified proteins (referred to as
ubiquitinomics or ubiquitylomics)8–11.
Here, we report a scalable and robust workflow for mass
spectrometry-based ubiquitinomics. By introducing a sodium
deoxycholate (SDC)-based lysis protocol, and exploiting data-
independent acquisition mass spectrometry (DIA-MS) coupled to
deep neural network-based data processing, we boost reprodu-
cibility, identification numbers, and quantitative accuracy. We
demonstrate the power of our method by comprehensively
mapping substrates of the deubiquitinase USP7, an actively
investigated anticancer drug target shown to regulate the tumor
suppressor p5312,13. Following inhibition with selective inhibitors,
we profile the dynamics of both the proteome and the ubiquiti-
nome at high temporal resolution. Combining the profiles of
ubiquitinated peptides with their corresponding protein abun-
dances not only allows us to define putative USP7 targets with
high confidence, but also to distinguish regulatory ubiquitination
leading to protein degradation from non-degradative events.
Results
Optimized cell lysis protocol for MS-based ubiquitinomics. For
improving depth and precision of ubiquitin-remnant peptide
quantification by mass spectrometry (MS), we optimized sample
preparation, MS, and data analysis. Despite its good performance
in regular proteomic analyses14,15, sodium deoxycholate (SDC)-
based protein extraction has only recently been explored for
ubiquitinomics applications16. We devised a modified version of
this lysis protocol, by supplementing the SDC buffer with
chloroacetamide (CAA). We reasoned that immediate boiling of
samples after lysis together with the high concentration of CAA
would increase ubiquitin site coverage, as CAA rapidly inactivates
cysteine ubiquitin proteases by alkylation. In contrast to the less
reactive CAA, it has been reported that iodoacetamide can cause
di-carbamidomethylation of lysine residues, which mimic
ubiquitin remnant K-GG peptides in terms of mass tag added
(both 114.0249 Da)17. We confirmed that CAA does not induce
any unspecific di-carbamidomethylation of lysine residues, even
when incubated at high temperatures (Supplementary Fig. 1a). To
directly compare SDC with the conventional urea-based lysis
buffer18, we treated HCT116 cells with the proteasome inhibitor
MG-132 for 6 h and extracted proteins with either buffer. After
tryptic digestion of proteins and immunoaffinity purification of
K-GG remnant peptides, we acquired the data in data-dependent
acquisition (DDA) mode. This led to the identification of 41,094
K-GG remnant peptides and we found on average 6 –GG mod-
ified lysine residues per protein. SDC-based lysis yielded on
average 38% more K-GG peptides than urea buffer (26,756 vs
19,403, n= 4, workflow replicates), without negatively affecting
the relative enrichment specificity (Fig. 1a, b, Supplementary
Fig. 1b and Supplementary Data 1). Moreover, SDC increased
both the number of precisely quantified K-GG peptides (i.e.,
peptides with a coefficient of variation (CV) < 20%) and the
reproducibility (Supplementary Fig. 1c, d).
In parallel, we digested different amounts of MG-132-treated
Jurkat cell lysate (31 µg–4 mg protein, n= 4 for each condition)
and enriched K-GG peptides before MS analysis. Here we also
quantified about 30,000 K-GG peptides from 2mg of protein
input, with identification numbers dropping below 20,000 for
inputs of 500 µg or less (Fig. 1c, Supplementary Fig. 1e and
Supplementary Data 2). Next, we benchmarked our SDC-based
lysis protocol against the recently described UbiSite method that
relies on urea lysis and immunoaffinity purification of
K-GGRLRLVLHLTSE remnant peptides resulting from Lys-C
digestion of ubiquitinated proteins19. We processed three of our
single-shot Jurkat samples (2 mg protein input) together with
three biological replicates (16 high pH reversed-phase fractions
each) of proteasomal inhibitor-treated Jurkat cells from Akimov
et al in MaxQuant20. UbiSite quantified on average 30% more
K-GG peptides in the three biological replicate samples. However,
our single-shot SDC workflow yielded a higher number of
precisely quantified peptides (CV < 20%) and we obtained a much
better enrichment specificity. Moreover, our protocol required
20-times less protein input, and only 1/10th of the MS acquisition
time per sample. We hence concluded that for a majority of
applications, the SDC-based lysis protocol would be advantageous
(Fig. 1d, e and Supplementary Data 3).
DIA-MS and neural network-based data processing boost
ubiquitinome coverage. Even though our revised lysis protocol
quantified up to 30,000 K-GG peptides in 125 min LC-MS runs,
due to the semi-stochastic sampling inherent to DDA, only about
50% of those identifications were without missing values in
replicate samples (Supplementary Fig. 1d). Consequently, the
number of robustly quantified K-GG peptides would be greatly
reduced in large sample series. To address this problem, we
explored data-independent acquisition (DIA), an acquisition
technique that is less susceptible to run-to-run variability21. Being
actively developed, DIA allows the identification and quantifica-
tion of very high numbers of peptides and proteins, for either
regular proteomes or phosphoproteomes22,23. Recently we
introduced DIA-NN, a deep neural network-based software,
which significantly increases proteomic depth and quantitative
accuracy for DIA, especially for samples of high complexity24. To
improve the analysis of DIA data for ubiquitinomics, we expan-
ded DIA-NN with an additional scoring module that ensures
confident identification of modified peptides, including K-GG
peptides (Methods).
Using a medium-length (75min) nanoLC gradient, we set up
optimized MS methods (Supplementary Data 4) and benchmarked
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our DIA workflow against state-of-the-art label-free DDA. For DIA
data processing we used DIA-NN in “library-free mode” (that is
searching against a sequence database without an experimentally-
generated spectral library), whereas for DDA data processing we used
MaxQuant20, with match-between-runs (MBR) enabled (Fig. 2a).
While DDA quantified 21,434 K-GG peptides on average per sample
from proteasome inhibitor-treated HCT116 cells, DIA more than
tripled this number, to 68,429 K-GG peptides (Fig. 2b). Besides
increased coverage, DIA showed excellent quantitative precision and
reproducibility. The median CV for all quantified K-GG peptides was
about 10%, and 68,057 peptides were quantified in at least three
replicates (Fig. 2c, d). 88% of ubiquitinated peptides detected by DDA
were also identified by DIA (Fig. 2e).
Although DIA-NN uses a rigorous approach to determine the
false discovery rate (FDR)24,25, it has not been validated for the
identification of K-GG peptides. We therefore determined the
identification confidence specifically for K-GG peptides experi-
mentally, and showed that it is comparable to that of the DDA
workflow and to a different DIA processing software (Supple-
mentary Note 1 and Supplementary Fig. 10). We also confirmed
the excellent quantitative accuracy and dynamic range of our DIA
workflow, using a pool of synthetic K-GG peptides spiked into a
yeast tryptic digest at different concentrations (Supplementary
Note 2 and Supplementary Fig. 11).
We next benchmarked the performance of DIA-NN when
using it in combination with an ultra-deep spectral library
generated by high-pH reversed-phase fractionation, consisting of
146,626 K-GG peptides (Methods). This yielded similar results as
library-free analysis, both in terms of coverage and reproduci-
bility (Fig. 2b–f). Finally, to directly compare DIA-NN’s
performance for analyzing ubiquitinomics data to another
software, we processed six raw files from Hansen et al.16 with
DIA-NN, revealing that DIA-NN identified on average 40% more
K-GG peptides (Fig. 2g).
DIA-MS ubiquitinomics for low protein amounts and high-
throughput analyses. When studying intracellular protein ubiqui-
tination by mass spectrometry, proteasome inhibitors are often used
to prevent degradation of the target of interest, thus conserving and
boosting the ubiquitin signal9,19,26. However, such compounds are
highly cytotoxic and result in an accumulation of newly synthesized,
misfolded proteins, thus activating the unfolded protein response,
one of the major cellular anti-stress mechanisms27. Moreover, pro-
teasome inhibition globally perturbs protein turnover by dis-
connecting protein ubiquitination from degradation8. To determine
whether our DIA-MS method is suitable for high coverage ubiqui-
tinomics in the physiological context and in case of low protein input,
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Fig. 1 Comparison of urea- and SDC-based cell lysis for mass spectrometry-based ubiquitinomics. a Fraction of unmodified and K-GG modified peptides
quantified from either urea or SDC lysates in MG-132-treated HCT116 cells. Four individual samples were processed for each lysis protocol, with 2 mg of
protein input per replicate. Only half of each sample was injected into the MS, which was operated in DDA mode (125min LC gradient). The raw data were
processed with MaxQuant, with “match between runs” (MBR) enabled. Gray dots show cumulative numbers of K-GG peptide identifications from four
replicates. b Overlap of quantified K-GG peptides and K-GG modified proteins with urea and SDC lysis buffers. c MS-quantified ubiquitinated peptides (K-
GG remnants) with different protein inputs in MG-132-treated Jurkat cells (6 h). Four individual samples were processed for each condition and the data
were acquired in single-shot mode using a 125 min DDA-MS method. The raw files were processed with MaxQuant, with match-between-runs (MBR)
activated. d Fraction of unmodified and K-GG modified peptides quantified with the SDC-based lysis protocol and with UbiSite19. Three single-shot runs of
enriched K-GG peptides from MG-132-treated Jurkat cells (2 mg of input, three replicates of samples as shown in c) were processed with MaxQuant (with
MBR) together with three biological replicates of bortezomib-treated Jurkat samples (16 high pH-reversed phase fractions for each replicate) from Akimov
et al. e Ranked K-GG peptide coefficients of variation (CVs) for samples shown in d. The 20% CV cut-off is marked. Source data are provided as a Source
Data file.
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Fig. 2 Side-by-side comparison of DDA and DIA for ubiquitinomics. a Schematic of data-dependent acquisition (DDA) and data-independent acquisition
(DIA) strategies. A K-GG peptide sample was prepared from MG-132-treated HCT116 cells and four replicates were acquired with each scan mode. The
DDA data were processed with MaxQuant (MBR enabled). For DIA data processing in DIA-NN, the same DIA-MS raw files were processed with either
library-free (no experimental spectral library) or library-based search (experimental spectral library obtained through high pH reversed-phase fractionation
of peptides prior to K-GG peptide enrichment). b Quantified K-GG peptides with 2mg of total protein as input for each replicate, in a side-by-side
comparison of DDA and DIA-MS. Four samples (injection replicates) were acquired with 75min single-shot LC-MS runs and processed with MaxQuant or
DIA-NN. Library-based DIA data analysis was performed with an ultra-deep K-GG peptide library generated by library-free DIA analysis of high-pH
fractions, as detailed in “Methods” (LF= library-free, lib= experimentally-generated spectral library). c Coefficients of variation (CVs, in %) for K-GG
peptides as shown in b are plotted for each method. Continuous lines demarcate the median and dashed lines the upper and lower quartiles. d Number of
identifications with 0, 1, 2, or 3 missing values in four replicates (samples shown in b) for DDA and DIA. e Venn diagram showing overlap of ubiquitinated
peptides (K-GG) identified by DDA and by DIA (DIA-NN’s library-free (LF) and spectral library-based (lib) approaches). f Scatter plot of Log2-
transformed K-GG peptide intensities obtained from library-free and spectral library-based search options in DIA-NN (n= 4, injection replicates). Values
indicate Pearson correlation coefficients. g Raw data of MG-132-treated HEK293 cells from Hansen et al. (Fig. 1d in the original manuscript, three workflow
replicates, each injected in duplicate and processed with Spectronaut’s directDIA mode16) were processed with DIA-NN (library-free mode). Plots show
identified K-GG peptides (unique peptide sequences) for both Software packages. Source data are provided as a Source Data file.
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amounts of either MG-132- or DMSO-treated cells. This revealed
that only 1mg of total protein was sufficient to reach saturation of
about 70,000 quantified K-GG peptides in MG-132-treated cells. In
DMSO-treated cells, however, increasing the input protein amount to
2mg augmented the number of quantified K-GG remnants from
39,000 to 46,000 (Fig. 3a and Supplementary Data 5). Notably, with
just 250 µg of protein, we quantified about 18,000 K-GG peptides in
the absence of proteasome inhibition, demonstrating the feasibility of
in-depth ubiquitinomics in the physiological context, even for low
protein amounts. As expected, a large fraction of K-GG peptides
increased in intensity upon proteasome inhibition and about 20,000
peptides increased >4-fold. On the other hand, about 1,500 and 6,200
K-GG peptides decreased in intensity >4-fold and >2-fold, respec-
tively. Among those were K-GG sites mapping to the C-terminus of
the histones H2A and H2B (K119 and K121, respectively), both of
which are well-studied ubiquitination sites involved in the regulation
of transcription and in DNA repair28,29. Besides these known sites,
we also identified uncharacterized K-GG sites on histones that were
strongly reduced in intensity upon MG-132 treatment, such as H2B-
K44 (Fig. 3b).
To evaluate the potential for higher throughput applications,
we set up DIA-MS methods for 15, 30, 45, and 60 min LC
gradients (Supplementary Data 4), and measured K-GG-enriched
HCT116 samples obtained from 2mg of protein input. This
showed that identification numbers improve massively from 15 to
30 min and from 30 to 45 min LC gradient length (+81% and
+31%, respectively), while the gain in K-GG peptide IDs was
moderate when further increasing MS acquisition time (8%, for
45–60 min and 6%, for 60–75 min). Even the 15 min LC-MS runs
consistently quantified more than 20,000 K-GG peptides with
good precision, demonstrating the potential for high-throughput
ubiquitinomics applications (Fig. 3c, d and Supplementary
Data 6). To benchmark DIA-NN’s performance for analyzing
samples not treated with proteasome inhibitors, we processed six
raw files (DMSO-treated) from Hansen et al in library-free mode.
Also in this comparison, DIA-NN clearly outperformed another
DIA data processing software, quantifying on average almost 75%
more K-GG peptides (Fig. 3e).
In-depth quantitative ubiquitin site profiling for USP7 sub-
strate identification. Currently, there are six clinically approved
drugs targeting different components of the UPS and several
more in preclinical testing4. The unbiased analysis of ubiquiti-
nation and deubiquitination events by MS-based ubiquitinomics
represents a powerful approach to develop or challenge a drug-
targeting hypothesis. However, key aspects such as the modula-
tion and the time-resolved interplay of protein ubiquitination and
degradation upon drug treatment have been difficult to address
on a truly proteome-wide scale. To meet this challenge, we
sought to profile the selective USP7 inhibitor FT67130 with our
DIA workflow in a series of time-course experiments. The deu-
biquitinase USP7 is a potential anticancer drug target that is
of particular interest for the treatment of hematological
malignancies12,13,31. For example, USP7 deubiquitinates and
stabilizes the E3 ligase Mdm2. As Mdm2 promotes p53 degra-
dation, inhibition of USP7 leads to p53-dependent tumor growth
suppression32,33. However, recent reports indicate that the ubi-
quitin signaling network regulated by USP7 may be much more
complex than initially thought30,33–35. In this context, global
proteomics approaches connecting early protein ubiquitination
with later changes in protein abundance represent an elegant tool
for pinpointing putative USP7 substrates with high confidence.
First, we quantified the ubiquitinomes and the proteomes at
five individual time points after USP7 inhibition with FT671 and
in the absence of proteasome inhibitors, to a depth of 45,000
K-GG peptides and over 10,000 proteins in each sample (Fig. 4a,
Supplementary Fig. 2 and Supplementary Data 7). Principal
component analysis (PCA) of the ubiquitinome captured the
variance of the different treatment times and revealed a clear
separation of DMSO and FT671 treatments at each time point.
We mapped at least one ubiquitination site on 8,087 proteins.
Already after 15 min of USP7 inhibition, we found 1,243
ubiquitinated peptides (mapping to 552 proteins) that were
significantly upregulated by more than twofold (Supplementary
Fig. 3). However, only 42 of these rapidly ubiquitinated proteins
were significantly downregulated by more than 20% over the 6 h
time course (Supplementary Data 7). These 42 factors most likely
represent direct USP7 targets marked for proteasomal degrada-
tion, and gene annotation enrichment analysis revealed that they
were overrepresented in transcriptional regulation (Zinc finger)
and the ubiquitin conjugation pathway (Fig. 4b, c and
Supplementary Data 8). We detected upregulated ubiquitination
sites for many reported USP7 targets, such as Trim27, UvssA, or
Mdm232,34,35. Besides these, we identified protein ubiquitination
that was followed by degradation for a number of proteins
without any reported connection to USP7 (e.g., Rnf220, L3mbtl2,
Pcgf6). However, the majority of ubiquitinated proteins, such as
USP7 itself or the USP7 interaction partner Daxx36, were not
degraded, even though multiple sites were strongly upregulated
throughout the time course (Supplementary Fig. 4). Our time-
resolved quantification of both the proteome and the ubiquiti-
nome in the absence of proteasome inhibition thus distinguishes
ubiquitination triggering apparent protein degradation from
nondegradative ubiquitin signatures.
Although five Mdm2 sites were significantly upregulated already
after 15min, its total protein level only transiently decreased to return
to baseline thereafter (Fig. 4d). This most likely resulted from a p53-
controlled increase of Mdm2 transcription, as expected and reported
previously33. In fact, ubiquitination sites on p53 initially decreased in
intensity, resulting in protein stabilization at later time points, which
coincided with an increased expression of its effector p21
(CDKN1A). Interestingly, besides these tumor suppressors, the
proto-oncogenes c-Fos and c-Jun were both upregulated upon USP7
inhibition (Fig. 4d).
To confirm that the observed increase in protein ubiquitination
is USP7-dependent, we knocked down USP7 expression using
two different siRNA pools, treated the cells with FT671 for 5 min
and extracted the proteins for ubiquitinome analysis. Again, we
quantified over 40,000 K-GG peptides and close to 10,000
proteins in each sample with very good precision and MS-based
quantification and Western blotting showed a fourfold reduction
in USP7 expression upon knockdown (Supplementary Fig. 5a–f).
While the compound treatment alone did not significantly alter
the expression of any of the detected proteins at 5 min of
treatment time, knockdown of USP7 induced profound changes
in protein expression, including a stabilization of p53 (Supple-
mentary Fig. 5g, h). As expected, we found that upon USP7
knockdown, for multiple targets identified in our earlier time
course experiment the measured protein ubiquitination after
FT671 treatment was strongly attenuated. This confirmed that
FT671 is selectively targeting USP7 and further validated multiple
previously unknown putative USP7 substrates (Fig. 4e and
Supplementary Data 9).
To further increase the confidence of defining primary USP7
targets and to get more insights into USP7-mediated signaling, we
mapped our ubiquitinomics data onto a USP7 interaction
network retrieved from BioGrid37. We identified significantly
upregulated sites at 15 min of FT671 treatment on 63% of high-
confidence physical USP7 interactors (evidence from four
experiments), strengthening the evidence that these proteins
likely represent direct USP7 targets (Fig. 4f).
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Fig. 3 DIA-MS ubiquitinomics for untreated samples and for high-throughput applications. a HCT116 cells were treated with DMSO or 10 µM MG-132
for 6 h and K-GG peptides from different protein inputs quantified by 75min single-run DIA-MS (library-free mode). Four samples were processed
independently for each tested protein input. b Dot plot of Log2-transformed K-GG peptide ratios (MG-132 vs DMSO) with 2mg of protein input, as shown
in a. Selected K-GG sites are highlighted. c Number of quantified K-GG peptides with 15, 30, 45, 60, and 75min DIA-MS runs. A K-GG peptide pool was
injected on the same instrument for each method (n= 4, injection replicates). The data were processed with library-free DIA. d Coefficients of variation
(CVs) distributions for K-GG peptides quantified in c. Continuous lines in the violin plots demarcate the median and dashed lines upper and lower quartiles.
e Shown are K-GG peptide numbers from DMSO-treated U2OS cells processed by Hansen et al. (Fig. 3 in the original manuscript, three biological
replicates, each injected twice16) and the same raw files processed with DIA-NN (library-free mode). Source data are provided as a Source Data file.
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The strikingly high regulation of protein ubiquitination already
at 15 min of USP7 inhibition pointed to a rapidly regulated,
complex signaling network. To further dissect which of the
upregulated ubiquitination sites are directly controlled by USP7,
we performed a high-resolution time-course experiment with
much faster sampling (at 2, 6 and 10min), again quantifying both
the ubiquitinome and the proteome in single-shot mode. At these
early time points, we did not observe significant protein changes
except for the downregulation of the E3 SUMO/ubiquitin ligase
Topors at 10 min (Supplementary Fig. 6a). Topors was strongly
degraded also in our initial time-course experiment and was below
detection limit already 15 min after USP7 inhibition (Fig. 4c). In
contrast, even at 2 min of FT671 treatment, we found 927
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twofold induced, with the strongest up-regulation seen for 22
K-GG peptides originating from USP7 itself, pointing at auto-
regulation. Orthogonal validation by enriching ubiquitinated
proteins with ubiquitin-binding domains, followed by either
Western blotting or MS analysis, independently confirmed these
results (Supplementary Fig. 7). We further detected 151
ubiquitinated peptides mapping to 33 of those proteins that were
ubiquitinated and degraded at later time points (15 min–6 h,
Fig. 4), again suggesting that these proteins are bonafide USP7
targets (Supplementary Fig. 6b and Supplementary Data 10).
Profiling of multiple USP7 inhibitors reveals a high overlap of
regulated ubiquitination sites. Structurally distinct compounds
targeting USP7 likely have different off-target effects. To deter-
mine such effects and to strictly define USP7 targets, we next
analyzed the ubiquitinome dynamics upon treatment with four
different USP7 inhibitors, namely FT671, FT827, GNE-6640 and
GNE-677630,33. Although PCA clearly separated the different
compounds from each other, we found an overall good correla-
tion of the significantly-regulated ubiquitinated peptides, reflect-
ing USP7 inhibition as the shared mode-of-action of the
compounds. As expected, the treatments with the structurally
similar compounds GNE-6640 and GNE-6776 overall correlated
best with each other. Furthermore, GNE-6776, but not GNE-6640
effects, correlated well with both FT671 and FT827, indicating a
greater difference in target selectivity (Fig. 5a–c). Interestingly,
several ubiquitination sites on USP7 were strongly induced by
both FT671 and FT827 and much less by GNE-6640 and GNE-
6776, probably reflecting a higher potency30,33 of the FT com-
pounds (Fig. 5d). Finally, to get a high-confidence list of primary
USP7 substrates targeted for proteasomal degradation, we
determined the overlap of degraded ubi-proteins in our time
course experiment and ubiquitinated proteins with sites sig-
nificantly and more than twofold increased by three out of the
four tested inhibitors. This revealed an overlap of 70%, further
strengthening the evidence that these are direct enzyme targets
directed for degradation (Fig. 5e and Supplementary Data 11).
Discussion
MS-based ubiquitinomics has seen enormous improvements over
the past years. Initially identifying just a handful of ubiquitination
sites, more recently the quantification of thousands of sites to
decipher ubiquitin signaling became commonplace6,26,38–40.
Until now, exclusively data-dependent acquisition mass spectro-
metry in combination with label-free, SILAC or TMT
quantification has been explored to address challenging biological
questions. Here we introduced an improved workflow featuring
an SDC-based lysis protocol, combined with DIA-MS and deep
neural network-based data processing using DIA-NN. We not
only identify very high numbers of ubiquitinated peptides, but
also quantify a large fraction of those with high precision.
Another strength of our method is the very high data com-
pleteness, a prerequisite for robust statistical analyses, in parti-
cular in medium- and large-scale experiments. Similar to this
study, in a simultaneously preprinted work, Mann and colleagues
recently reported the advantages that DIA-MS offers over label-
free DDA in ubiquitinomics16. However, despite using shorter
chromatographic gradients, our improved lysis protocol along
with our deep neural network-based processing software (DIA-
NN), which we specifically optimized for ubiquitinomics, allowed
us to double the numbers of quantified K-GG peptides.
DIA-based experiments typically employ spectral libraries,
which are built by either high pH reversed-phase or gas-phase
fractionation of peptides23,41,42. Library-free searches instead use
in silico generated spectral libraries, which are particularly
advantageous in case of PTM analyses, where experimental
library generation can be very laborious and require large protein
amounts23. We demonstrate that library-free DIA can perform
comparably well to a DIA analysis workflow based on
experimentally-generated spectral libraries, and rigorously vali-
date its identification confidence as well as its quantification
accuracy. Without the need for a dedicated spectral library, our
workflow is ideally suited for applications with minimal sample
amounts, such as tumor biopsies, primary cells or laser micro-
dissected tissue samples43. Nevertheless, for screening-type
applications, we recommend generating a spectral library,
which speeds up data processing considerably without compro-
mising on analytical depth.
The gain in sensitivity, throughput, and quantitative precision
achieved by our workflow allowed us to introduce an advanced
strategy for probing DUB substrates: upon chemical enzyme
inhibition, we track the dynamic changes in both the proteome
and the ubiquitinome at high temporal resolution. By doing so,
early-induced ubiquitination events on a target protein can be
connected to its degradation at later time points, allowing the
pinpointing of putative substrates with high confidence. Never-
theless, to confirm direct DUB targets, orthogonal assays such
as in vitro deubiquitination assays or proximity-labeling experi-
ments are required. Besides available inhibitors of the UPS, gene
expression knockdown technologies such as CRISPRi44, in com-
bination with our DIA-MS ubiquitinomics workflow, could also
Fig. 4 Identification of USP7 substrates in a time-course experiment. a Schematic of the USP7 inhibitor time-course experiment. HCT116 cells were
treated with DMSO or 10 µM of FT671 and harvested in SDC buffer at the indicated time points. After tryptic digestion of 2 mg of total protein per sample,
both the ubiquitinome and the proteome were acquired in single-shot DIA mode and the resulting raw files processed using DIA-NN. b Volcano plots of the
ubiquitinome (15min) and the proteome (6 h) after FT671 treatment are shown on the left. Significantly-regulated proteins and K-GG peptides (LIMMA52,
5% FDR) are colored (Log2 fold changes −1 < x < 1 in blue and x < −1 or x > 1 in red). The Venn diagram shows significantly and >2-fold ubiquitinated
proteins at 15min (red), and ubiquitinated proteins that were significantly downregulated by more than 20% over the 6 h time course (blue). The
overlapping proteins were significantly enriched for categories such as zinc finger and ubiquitin-protein ligase activity. BH FDR= Benjamini–Hochberg false
discovery rate. c Heat map of proteins that were significantly downregulated by more than 20% upon FT671 treatment (or more than 50%, in magenta)
and that showed significant, and more than twofold induction of at least one ubiquitination site at 15 min. Ubiquitin peptide profiles were averaged and both
data were matched based on gene level. Topors was included in the heatmap - its protein intensities were below detection limit (missing values, in gray)
because it was rapidly degraded upon FT671 treatment. d Profiles of Log2 fold changes (FT671/DMSO) at different time points for different cell cycle
regulators upon USP7 inhibition. Plotted are mean ± SEM. n= 4 biological replicates. e After transfection with different siRNAs (Control, USP7_1, USP7_2)
for 48 h, HCT116 cells were treated with DMSO/10 µM FT671 for 5 min. Shown are Log2 fold changes (FT671/DMSO) of all quantified K-GG remnants for
siRNAs targeting USP7 (y-axis on both plots) or a control siRNA (x-axes). Selected targets found to be regulated in the time course experiment (Fig. 4a–d)
are colored. f Significantly upregulated ubiquitinated peptides at 15min of FT671 treatment were mapped onto a BioGrid37 network for reported USP7
interacting proteins (filtered for four evidences). The proteins were colored according to the peaking time of the ubiquitin signal (averaged profiles for
significantly upregulated peptides). Source data are provided as a Source Data file.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-25454-1












































































FT671 FT827 GNE-6640 GNE-6776
e
Fig. 5 Profiling of multiple USP7-targeting compounds by DIA ubiquitinomics. a HCT116 cells were treated with four structurally distinct USP7 inhibitors
for 1 h. Shown is a principal component analysis (PCA) of the ubiquitinomics data. b Log2 fold changes (lower left part), density distributions (middle part),
and Pearson correlations of significantly regulated K-GG peptide intensities with four different compounds targeting USP7. c Venn diagrams of significantly
up- and downregulated K-GG peptides with the different compounds. d Dot plot showing Log2 fold changes (USP7-targeting compound vs DMSO) of
K-GG peptides for FT671, FT827, GNE-6640, and GNE-6776. K-GG peptides mapping to USP7 are highlighted. e Fold changes of ubiquitinated peptides
(FT671/DMSO, Log2-transformed) for four structurally distinct USP7 inhibitors. Shown are ubiquitin peptide profiles for those proteins that harbor
significantly and >2-fold increased ubiquitination sites with three out of four USP7 inhibitors and that are ubiquitinated and degraded upon FT671 treatment
(see Fig. 4). Source data are provided as a Source Data file.
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be leveraged for future systematic DUB/E3 ligase substrate
screens.
We applied our method to characterize USP7 targets in an
unbiased manner. Besides confirming known substrates, such as
Mdm2, we also mapped actual modification sites on these pro-
teins. On top of that, we uncovered a set of transcriptional reg-
ulators and E3 ligases as putative substrates directed for
proteasomal degradation. Interestingly, using a combination of
different inhibitors and MS-based proteomics to detect down-
regulated proteins (without concomitant ubiquitinome profiling),
a recent report identified similar proteins as bona fide USP7
targets, namely a number of DNA repair enzymes and E3
ligases45. While protein abundance changes can in theory be used
as a readout for mapping DUB enzyme targets, a major limitation
of such an approach is that direct targets cannot be distinguished
from secondary regulations, and regular proteomics does not
allow identifying ubiquitination sites. Our method overcomes this
hurdle by simultaneously recording protein ubiquitination and
protein abundances.
We observed an ultra-fast response after USP7 inhibition, with
about 1,000 upregulated ubiquitinated peptides mapping to
hundreds of proteins, even at the earliest time point tested (2 min,
Supplementary Data 10). Surprisingly, only a very small subset of
these targets was actually degraded at later time points, and this
raises several questions for follow-up studies. For example, what
are the ubiquitin chain types that USP7 acts upon or what ubi-
quitination threshold must be reached before a protein is targeted
for degradation by the proteasome. Another open question is
whether DUBs other than USP7 have a similar large target
spectrum.
In conclusion, our optimized ubiquitinomics workflow accu-
rately and consistently quantifies tens of thousands of ubiquiti-
nated peptides at high throughput and enables precise time-
resolved analysis of in vivo ubiquitination dynamics. We mapped
hundreds of ubiquitination sites on both known and not reported
USP7 substrates and determined their impact on protein abun-
dance regulation.
Besides direct enzyme-substrate relationship investigation, our
method will be useful to define modes-of-action of drugs directed
against different components of the UPS. Furthermore, it will aid
the better understanding of ubiquitin signaling in processes such
as DNA repair or protein/organellular turnover, which can lead
to cancer formation or neurodegeneration, if dysregulated.
Methods
Reagents. MG-132 (474787), Bortezomib (5043140001), 2-chloroacetamide (CAA,
22790), tris(2-carboxyethyl)phosphine hydrochloride (TCEP, C4706), sodium
deoxycholate (SDC, 30970), dimethyl pimelimidate dihydrochloride (DMP,
D8399), ethanolamine (411000), Na2HPO4 (S9763), 3-(N-morpholino)propane-
sulfonic acid (MOPS, M5162), sodium azide (S2002), N-ethylmaleimide (E3876),
PR-619 (SML0430) and sodium tetraborate decahydrate (S9640) were from Mil-
lipore Sigma. Ethylenediaminetetraacetic acid (EDTA, 108418), Tris(hydrox-
ymethyl)-aminomethan (Tris, 108382), trifluoracetic acid (TFA, 108178),
ammonium hydroxide (NH4OH, 533003), sodium chloride (106404), ethyl acetate
(103649), acetonitrile (ACN, 100030) from Merck. RNAiMAX from Thermo Sci-
entific (13778075). Formic acid (FA, 56302) from Fluka. BSA (01400) from Biomol.
FT671 (5-((1-(4,4-Difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoyl)-4-hydro-
xypiperidin-4-yl)methyl)-1-(4-fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyr-
imidin-4-one, AOB37855, Purity =98% by HPLC), GNE-6640 (4-[2-Amino-4-
ethyl-5-(1H-indazol-5-yl)-3-pyridyl]phenol, AOB37854, Purity =98% by HPLC)
and GNE-6776 (6′-Amino-4′-ethyl-5′-(4-hydroxyphenyl)-N-methyl-[3,3′
-bipyridine]-6-carboxamide, AOB37852, Purity= 98% by HPLC) from AOBIOUS,
FT827 (Ethenesulfonamide, N-[4′-[[4-[(1,4-dihydro-1-methyl-4-oxo-5H-pyrazolo
[3,4-d]pyrimidin-5- yl)methyl]-4-hydroxy-1-piperidinyl]carbonyl][1,1′-biphenyl]-
2-yl]-, HY-111350, Purity= 98.48% by LC/MS) from MedChemExpress and
Trypsin/LysC mix (V5071 or V5072) from Promega. PTMScan® Ubiquitin Rem-
nant Motif (K-ε-GG) Kit (#5562) from Cell Signaling Technology. The mix of
hundred synthetic K-GG peptides was obtained from JPT peptide technologies
(SpikeMix™ PTM-Kit 47 - Lys(GG) and was resuspended in 100 µl of 0.1% formic
acid by sonication. The tryptic yeast digest from Promega (V7461) and the E. coli
digest from Waters (186003196). Both were resuspended in 100 µl of 0.1%
formic acid.
Cell culture, drug treatments, transfection, and cell lysis. HCT116, MM.1S, and
Jurkat 6.1 were from ATCC. HCT116 were cultured in DMEM, 10% FCS, 4 mM
L-glutamine and 1 mM sodium pyruvate. Jurkat 6.1 and MM.1S were grown in
RPMI, 10% FCS, 2 mM L-Glutamine, and 1 mM Sodium pyruvate. MG-132,
FT671, FT827, GNE-6640, and GNE-6776 were dissolved in DMSO to prepare a
10 mM stock solution. Cells were treated with either DMSO or the indicated
compounds, washed twice with ice-cold PBS, and harvested using freshly prepared
SDC buffer (room temperature) or urea buffer (chilled to 4 °C). The SDC buffer
contained 1% SDC, 10 mM TCEP, 40 mM CAA, 75 mM Tris-HCl at pH= 8.5 and
its pH was adjusted to 8.5 with 1 N NaOH. The urea buffer contained 8M urea,
1 mM EDTA, 1 mM CAA, 150 mM NaCl, 50 mM Tris-HCl pH 8.0, 2 µg/ml
aprotinin, 10 µg/ml leupeptin, 50 µM PR-619 and 1 mM PMSF, which was added
immediately before use. The SDC lysates were heated to 95 °C for 10 min while
shaking at 750 rpm in a Thermomixer (Eppendorf) and then sonicated for 10 min
(10 × 30 s on/off cycles) using a Bioruptor® Pico sonication device (Diagenode) (for
volumes <2ml) or a ultrasonic probe device (Bandelin Sonopuls, 1 min, energy
output ~40%, for volumes >2 ml). For the SDC/urea comparison in Fig. 1, the urea
lysates were processed as described previously18. Briefly, the cell pellet was
homogenized by pipetting up and down and the lysate cleared by centrifugation at
20,000 × g for 10 min at 4 °C. The supernatant was then transferred to a new tube.
For siRNA-mediated knockdown of USP7, HCT116 cells were transfected with
either a control siRNA (QIAGEN, 1022076) or two different siRNAs targeting
USP7 (siUSP7_1= QIAGEN FlexiTube, 1027417, siUSP7_2= Sigma Aldrich,
EHU131171) with RNAiMAX (Thermo Scientific), following the vendor’s protocol.
The cells were transfected twice (at day 1 (0 h) and day 2 (24 h)) and drug
treatment (DMSO or 5 µM FT671 for 5 min) followed by cell lysis performed at
48 h post-transfection.
Ubiquitin domain pulldown experiments. HCT116 cells were treated with 10 µM
MG-132, alone or in combination with 10 µM FT671 for 15 min. Cells were har-
vested in ice-cold lysis buffer (50 mM Tris-HCl pH 7.5, 0.15M NaCl, 1 mM EDTA,
1% NP-40, 10% glycerol, freshly supplemented with 50 µM PR-619 and 10 mM
NEM (N-ethylmaleimide) and spun at 14,000 g for 10 min. The supernatant was
transferred to a fresh tube and the protein concentration determined using the
BCA assay (Thermo Scientific, 23225). 20 µl of TUBE2 agarose matrix (LifeSensors,
UM402) were added to 2 mg of total lysate, followed by incubation at 4 °C for 1 h
on a rotor wheel. The beads were collected by centrifugation and washed three
times each with 1 ml of TBS (20 mM Tris-HCl pH 8.0, 0.15 M NaCl)-0.1% Tween-
20. The proteins were eluted using a 5× SDS-sample buffer (200 mM Tris pH 6.8,
5% (v/v) ß-Mercaptoethanol (freshly added), 5% (w/v) SDS, 50% Glycerol, 0.25%
(w/v) Bromphenolblau), separated on SDS-PAGE followed by Western blotting. In
short, proteins were transferred to a nitrocellulose membrane and the membrane
was blocked in 5% milk/TBS-0.1% Triton for 1 h at room temperature. After
washing for three times with TBS-0.1% Triton, the membrane was incubated
overnight with a primary USP7 antibody (Cell signaling technology, 4833, 1:1000
in 2% BSA-TBS-0.1% Triton) at 4 °C. The following day, the membrane was
washed, incubated with a secondary HRP-linked (Rockland (611–1302), 1:10,000
in 2% BSA-TBS-0.1% Triton) anti-rabbit antibody and USP7 detected by chemi-
luminescence (ChemiDoc, Biorad). For MS analysis, proteins were digested on-
bead. After washing with 3 × 1ml TBS-0.1% Tween-20 and 1 × 1ml TBS, 100 µl of
SDC buffer were added to the beads, followed by incubation at 95 °C for 10 min.
After cooling to RT, 0.5 µg of trypsin was added to each sample, followed by
overnight incubation at 37 °C in a thermomixer. The following day, 100 µl of 99%
isopropanol/1% TFA were added and the peptides were desalted using SDB-RPS
STAGE tips. STAGE tips were activated using 100 µl of 99% isopropanol/1% TFA,
then washed with 75 µl of 80% ACN/5% NH4OH, followed by two washes with
99% isopropanol/1% TFA (75 µl each). The samples were then loaded onto the tips
and washed twice with 99% isopropanol/1% TFA (200 µl each) and additional two
times with 0.2% TFA (200 µl each). Finally, the peptides were eluted with 75 µl of
80% ACN/5% NH4OH, speed-vac dried, and resupended in 20 µl of 0.1% formic
acid. After peptide concentration estimation on the nanodrop (Thermo Scientific),
the concentration was set to 0.4 µg/µl and 2 µl were injected into the mass spec-
trometer (800 ng).
Crosslinking of K-GG antibody. Crosslinking was performed as described
previously18. In brief, antibody-bound beads were washed with 3 × 1ml of 100 mM
sodium tetraborate (pH 9.0) and then crosslinked by incubating with 1 ml of
20 mM DMP/100 mM sodium borate (pH= 9.0) for 30 min at room temperature.
The crosslinking buffer was removed and the reaction stopped by washing with 2 ×
1 ml of 200 mM ethanolamine (pH= 9.0), followed by incubation with 1 ml of
200 mM ethanolamine (pH= 9.0), with end-over-end rotation at 4 °C for 2 h.
Finally, the beads were washed with 3 × 1ml of IP buffer and either directly used or
conserved for up to 2 weeks in 1× phosphate-buffered saline (PBS)/0.02%
sodium azide.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-25454-1
10 NATURE COMMUNICATIONS |         (2021) 12:5399 | https://doi.org/10.1038/s41467-021-25454-1 | www.nature.com/naturecommunications
K-GG peptide enrichment and LC-MS/MS sample preparation. Protein con-
centrations were determined using the BCA assay (for experiments in Fig. 1a) or
the 660 nm assay (all other experiments, Thermo Fisher Scientific). 2 mg of urea
lysate for each replicate was reduced with 5 mM DTT for 45 min and then alkylated
with 10 mM CAA for 30 min in the dark before digestion. Proteins were digested
with trypsin/Lys-C mix overnight at 37 °C (SDC lysates) or at room temperature
(urea lysates) with a 1:50 enzyme to protein ratio. For urea samples, the digestion
was stopped by adding TFA to a final amount of 0.1% (v/v) and peptides were
desalted using C18 cartridges (Sep-Pak tC18, WAT036790) as follows: (a) con-
ditioning with 5 ml of ACN; (b) conditioning with 5 ml of 50% ACN/0.1% FA; (c)
equilibration with 4 × 5ml of 0.1% TFA; (d) loading of the sample, (e) washing
with 4 × 5ml 0.1% TFA, (f) elution with 2 × 3ml 50% ACN/0.1% FA. For SDC-
lysed samples, the digestion was stopped by adding two volumes of 99% ethyla-
cetate/1% TFA, followed by sonication for 1 min using an ultrasonic probe device
(energy output ~40%). The peptides were desalted using 30 mg (for < 1 mg of
input, 8B-S029-TAK) or 100 mg (for up to 2 mg of input, 8B-S029-EBJ) Strata-X-C
cartridges (Phenomenex) as follows: (a) conditioning with 1 ml/3 ml (for 30 mg
and 100mg cartridges, respectively) of isopropanol; (b) conditioning with 1 ml/
3 ml of 80% ACN/5% NH4OH; (c) equilibration with 1 ml/3 ml of 99% ethylace-
tate/1% TFA; d) loading of the sample; e) washing with 2 × 1 ml/3 ml of 99%
ethylacetate/1% TFA; f) washing with 1 ml/3 ml of 0.2% TFA; g) elution with 2 ×
1ml/3 ml of 80% ACN/5% NH4OH. The eluates were snap-frozen in liquid
nitrogen and lyophilized overnight. K-GG peptide enrichment was performed as
described with some minor modifications18. Briefly, peptides were resuspended in
1 ml of cold immunoprecipitation (IP) buffer (50 mM MOPS pH 7.2, 10 mM
Na2HPO4, 50 mM NaCl) and incubated with 40 µl of a 25% slurry of cross-linked
K-GG antibody-bead conjugate (corresponding to 10 µl beads/IP) for 2 h at 4 °C
with end-over-end rotation. Beads were then washed twice with 1 ml of IP buffer
and an additional time with cold Milli-Q® water. After removing all the super-
natant, the beads were incubated with 200 µl of 0.15 % TFA at room temperature
while shaking at 1,400 rpm. After briefly spinning, the supernatant was recovered
and desalted using in-house prepared, 200 µl two plug StageTips46 with SDB-RPS
(3M EMPORETM, 2241; for SDC) or C18 (3 M EMPORETM, 2215; for urea). SDB-
RPS StageTips were conditioned with 60 µl isopropanol, 60 µl 80% ACN/5%
NH4OH, and 100 µl 0.2% TFA. The K-GG enrichment eluate (0.15% TFA) was
directly loaded onto the tips followed by two washing steps of 200 µl 0.2% TFA
each. Peptides were eluted with 80% ACN/5% NH4OH. For C18, StageTips were
equilibrated with 60 µl ACN and 2 × 60 µl 0.1% FA before sample loading.
StageTips were washed with 2 × 60 µl or 0.2% TFA and peptides eluted with 60 µl
of 50% ACN/0.1% FA. Peptides were Speedvac dried and then resupended in 10 µl
of 0.1% FA, of which 4 µl were injected into the mass spectrometer. For total
proteome measurements, a 50 µl aliquot of desalted peptide eluate was transferred
to a 0.5 ml tube, Speedvac dried and resuspended in 15 µl of 0.1% FA. The peptide
concentration was estimated using a NanodropTM device (Thermo Fisher Scien-
tific) and adjusted to 0.4 µg/µl with 0.1% FA, of which 2 µl (800 ng) were injected
into the mass spectrometer.
High-pH reversed-phase fractionation. HCT116 cells were treated with MG-132
(10 µM) or FT671 (10 µM) for 6 h before lysis with SDC buffer (see “Cell culture,
drug treatments and cell lysis” for details). 40 mg of each lysate were combined
before overnight digestion (37 °C) with Trypsin/LysC in a 1:50 enzyme to protein
ratio. The resulting peptides were desalted using Strata-X-C cartridges (Phenom-
enex) as described in “K-GG peptide enrichment and LC-MS/MS sample pre-
paration”. The lyophilized peptides were resuspended in 0.1% FA and fractionated
using a Zorbax 300SB-C18 column (Agilent Technologies) on an ÄKTA HPLC
system (GE Healthcare). Fractionation was performed with a flow rate of 3 ml/min
and with a constant flow of 10% 25mM ammonium bicarbonate, pH 10. Peptides
were separated using a linear gradient of ACN from 5% to 35% over 45 min,
followed by a 5-min increase to 60% ACN and ramping to 70% over 3 min.
Fractions were collected at 60-s intervals in a 48-well plate to a total of 36 fractions
and then pooled to obtain 12 fractions (A1-C1-E1, A2-C2-E2 etc.). All fractions
were acidified by adding FA to a final amount of 0.1% and then lyophilized.
Peptides were subsequently resuspended in 1000 µl 0.1% TFA and desalted using
Strata-X-C cartridges (Phenomenex) as described. Lyophilized peptides of each
fraction were resuspended in 1 ml of IP buffer and enriched for K-GG peptides.
Each fraction was injected trice into the mass spectrometer (36 measurements in
total) and the data were acquired with a 75 min LC-MS method (DIA). The data
were processed in DIA-NN, using the library-free setup.
LC-MS/MS measurements. Peptides were loaded on 40 cm reversed-phase col-
umns (75 µm inner diameter, packed in-house with ReproSil-Pur C18-AQ 1.9 µm
resin [ReproSil-Pur®, Dr. Maisch GmbH]). The column temperature was main-
tained at 60 °C using a column oven. An EASY-nLC 1200 system (ThermoFisher)
was directly coupled online with the mass spectrometer (Q Exactive HF-X,
ThermoFisher) via a nano-electrospray source, and peptides were separated with a
binary buffer system of buffer A (0.1% formic acid (FA) plus 5% DMSO) and
buffer B (80% acetonitrile plus 0.1% FA plus 5% DMSO), at a flow rate of 250 nl/
min (for 75 min and 125 min gradients). For the 60 min method, a flow rate of
300 nl/min was used. For the 30 min and 45 min gradients, a flow rate of 350 nl/
min was used and for the 15 min DIA method, a 15 cm column and a flow rate of
500 nl/min were used. The mass spectrometer was operated in positive polarity
mode with a capillary temperature of 275 °C.
The DDA method consisted of a MS1 scan (m/z= 300–1650, R= 60,000,
maximum injection time= 20 ms, spectrum data type= profile) followed by TopN
MS/MS scans (N= 15). These were acquired at R= 15,000, AGC target= 1e5,
maximum injection time= 28 ms, isolation window 1.4 Th, NCE= 27 and a scan
range of 200–2000m/z.
The DIA methods consisted of a MS1 scan (m/z= 300-1,650) with an AGC
target of 3 × 106 and a maximum injection time of 60 ms (R= 120,000). DIA scans
were acquired at R= 30,000, with an AGC target of 3 × 106, “auto” for injection
time and a default charge state of 4. The spectra were recorded in profile mode and
the stepped collision energy was 10% at 25%. The number of DIA segments was set
to achieve an average of 4–5 data points per peak (Supplementary Data 4).
Scoring of ubiquitination sites implemented in DIA-NN. A set of scores that
reflect MS2-level evidence for detection of the modified peptide were implemented
in DIA-NN. In DIA proteomics, peptides are matched not just to a single spectrum,
but to a series of consecutive spectra, wherein each peptide fragment ion gives rise to
an elution profile. In the absence of interfering signals, originating from co-
fragmenting peptides that share fragments with the same masses, the elution profiles
of fragments of a peptide correlate. Detecting these correlations is the primary
method that enables matching peptides to the data in DIA proteomics24,47,48. In
DIA-NN, this concept is explored to boost the confidence of K-GG peptide iden-
tification. When assessing the candidate elution peaks, which could potentially
originate from a particular peptide, DIA-NN always designates one of its fragments
as the “best”, based on which fragment has an elution profile that best correlates
with elution profiles of other fragments. The elution profile of the “best” fragment is
then considered representative of the true elution profile of the peptide itself24. The
“quality” of signals corresponding to all other fragments as well as to the extracted
elution profile of the precursor itself (MS1 level) is then assessed based on how well
their elution profiles correlate with the elution profile of the “best” fragment, with
high correlation being indicative that the fragments likely originate from the same
precursor. DIA-NN leverages this principle for confident K-GG detection. A
number of scores are calculated, using sums of such correlations, for all the frag-
ments that contain/do not contain the modified residues/other potential mod-
ification sites (in different combinations of these conditions), and used to determine
the confidence of modified peptide identification (Supplementary Fig. 8).
Raw data processing. MS raw files acquired with DDA mode were analyzed using
MaxQuant20, version 1.6.17.0 (maxquant.org), whereas files acquired in DIA mode
were processed using DIA-NN24, version 1.8 (https://github.com/vdemichev/DIA-
NN). Reviewed UniProt entries (human, SwissProt 11-2020 [9606], 42,395 entries;
yeast [559292], SwissProt 11-2020, 6,750 entries and E. coli [83333], SwissProt 01-
2021, 4,532 entries) were used as protein sequence database for both MaxQuant and
DIA-NN searches. For MaxQuant, the standard settings were used (enzyme=
trypsin/P, two missed cleavages, carbamidomethylation of cysteines as fixed mod-
ification and protein N-terminus acetylation and oxidation of methionine as variable
modifications) and K-GG was added as a variable modification. “Match between
runs” (MBR) was enabled where indicated. For DIA-NN, one missed cleavage and a
maximum of two variable modifications per peptide were allowed (acetylation of
protein N-termini and oxidation of methionine). Carbamidomethylation of cysteines
was set as fixed modification and K-GG was added in case of ubiquitinomics. Unless
specified, all ubiquitinomics data analyses were carried out using library-free analysis
mode in DIA-NN. All proteome data analyses were performed in library-free mode.
For details on setup of DIA-NN searches, see Supplementary Fig. 9. For library-free
searches, “deep learning-based spectra and RTs prediction” was enabled. MBR was
enabled. This instructs DIA-NN to follow the two-step workflow as described
previously24. Briefly, DIA-NN first generates a spectral library from DIA data using
all identifications in the specified raw files. The library generation is performed using
both global (experiment-wide) and run specific precursor FDR filters of 1%. This
library is then used as a spectral library in a second search. The quantification
strategy was set to “Robust LC (high precision)”. Spectronaut (v.
14.10.201222.47784) was run with default settings, except PTM localization was
enabled and set to 0, while protein q-value filtering was disabled.
Bioinformatic data analysis. Modification-specific peptides of MaxQuant outputs
(DDA) were filtered to exclude reverse hits and contaminants. Counts of K-GG
and non-K-GG peptides, missing values, and CVs were computed using the Per-
seus software49. Specifically, the modification-specific peptide output table from
MaxQuant was filtered for unique peptide sequences for both K-GG and non-K-
GG peptides.
For DIA-NN ubiquitinomics outputs, precursors were aggregated to peptides by
averaging normalized precursor intensities. Coefficients of variation were
computed on the K-GG peptide raw intensities and the plots were created with R
(version 3.6.1). The GO term enrichment analysis was done with Perseus49.
DIA-NN outputs for Figs. 4 and 5 and associated supplementary figures were
further processed with R. K-GG precursor intensities were aggregated to peptides
using the MaxLFQ50 algorithm, as implemented in the DIA-NN R package
(https://github.com/vdemichev/DIA-NN-rpackage/). K-GG peptide to site
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mapping was done using reviewed entries of the human UniProt database
(SwissProt, release 11-2020, 42,395 entries). The peptide intensities were
normalized by median sample scaling before differential expression analysis.
The proteome raw data were processed with the library-free search modey in
DIA-NN. Instead of using the protein groups created by DIA-NN, protein
inference was performed in-house following the logic of the ID Picker51 algorithm.
Significance testing of log2-transformed intensities was performed with
LIMMA52 on all peptides/proteins present in more than 50% of samples; inhibitor
treatments were compared to their corresponding DMSO controls at each time
point. Multiple testing-corrected q-values <0.05 were considered as significant. For
comparing proteome and ubiquitinome data, protein groups of each dataset were
disaggregated into individual UniProt identifiers and then mapped between the
data sets. For individual plots, the protein groups of the ubiquitinome data sets
along with K-GG site positions were used. Hierarchical clustering was performed
using Ward’s method on Euclidean distances, separately for proteomes and
ubiquitinomes. The data was visualized in Spotfire (version 7.12.0).
Cytoscape (version 3.7.2, cytoscape.org) was used for mapping the combined
interactomics data from BioGrid37 to the ubiquitinomics data from this study.
BioGrid interaction data (version 3.5.186) was filtered for human proteins with
physical interactions with USP7 in at least four studies. Ubiquitination sites were
mapped onto USP7 and its interactors, if they showed significant upregulation at
15 min. Proteins without significant ubiquitination regulation are not shown.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The mass spectrometry proteomics raw data and the corresponding processing reports
generated in this study have been deposited to the ProteomeXchange Consortium (http://
proteomecentral.proteomexchange.org) via the PRIDE53 partner repository with the
dataset identifier PXD023889. Previously published data used in various benchmark
experiments are available under the accession codes PXD019854 and PXD006201. Source
data are provided with this paper.
Code availability
DIA-NN is freely available for download at https://github.com/vdemichev/diann.
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